NEOSCAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEOSCAN is an injectable diagnostic agent approved by GE HealthCare in 1978 as an NDA product. The mechanism of action and specific indications are not publicly detailed in available data, but the injectable route suggests use in imaging or diagnostic procedures. This is a mature, legacy product approaching loss of exclusivity.
LOE Approaching
As a legacy diagnostic product nearing loss of exclusivity with minimal linked job opportunities, this portfolio asset likely operates with a lean, cost-focused team focused on market defense rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Started Oct 2011
42 enrolled
Lung Cancer
Career Relevance
NEOSCAN offers limited career development opportunities due to its mature lifecycle, legacy status, and minimal linked job openings (0 recorded). Roles are primarily in cost-containment, compliance, and operational sustainment rather than growth or innovation.
Product Manager
Worked on NEOSCAN at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.